Showing 1691-1700 of 2657 results for "".
- Bausch + Lomb to Present Scientific Data and Analyses at Upcoming Eye Care Meetingshttps://modernod.com/news/bausch-lomb-to-present-scientific-data-and-analyses-at-upcoming-eye-care-meetings/2480388/Bausch + Lomb announced that seven scientific posters involving the company's products, as well as data from the company's Antibiotic Resistance Monitoring in Ocular MicRoorganisms (ARMOR) surveillance study, will be presented during the annual meetings of the American Academy o
- Aerie Pharmaceuticals Announces Positive Phase 3 Topline Results for Netarsudil Ophthalmic Solution 0.02% Clinical Trial in Japanhttps://modernod.com/news/aerie-pharmaceuticals-announces-positive-phase-3-topline-results-for-netarsudil-ophthalmic-solution-002-clinical-trial-in-japan/2480342/Aerie Pharmaceuticals reported positive topline results for the company’s phase 3 clinical trial in Japan evaluating netarsudil ophthalmic solution 0.02% versus ripasudil hydrochloride hydrate ophthalmic solution 0.4%. The results showed that netarsudil 0.02% once daily was s
- Aurion Biotech Announces Strategic Investments in Manufacturinghttps://modernod.com/news/aurion-biotech-announces-strategic-investments-in-manufacturing/2480275/Aurion Biotech announced it has appointed Tim Largen as vice president of manufacturing. Mr. Largen is based in Seattle and will lead strategy and development of Aurion Biotech’s global cell manufacturing capabilities. His role will include managing Aurion Biotech’s internal team and
- Belkin Laser Appoints Andrew Webb as Chief Commercial Officerhttps://modernod.com/news/belkin-laser-appoints-andrew-webb-as-chief-commercial-officer/2479316/Israel-based medical device company Belkin Laser has announced the appointment of Andrew Webb as Chief Commercial Officer. Under Mr. Webb’s guidance, the company’s commercial and go-to-market strategy will be rolled out in anticipation of a controlled launch in
- CDC Endorses Use of Pfizer, BioNTech COVID-19 Vaccine in Teens as Young as 12https://modernod.com/news/cdc-endorses-use-of-pfizer-biontech-covid-19-vaccine-in-teens-as-young-as-12/2479204/An advisory panel of the US Centers for Disease Control and Prevention (CDC) on Wednesday voted 14-0, with one recusal, to endorse the FDA’s recent decision to extend use of Pfizer and BioNTech’s COVID-19 vaccine BNT162b2 to 12- to 15-year-olds, according to FirstWord. The recommendat
- Nanoform and Nacuity Pharmaceuticals Sign Technology Proof of Concept Agreement for Two Ophthalmic Drug Candidateshttps://modernod.com/news/nanoform-and-nacuity-pharmaceuticals-sign-technology-proof-of-concept-agreement-for-two-ophthalmic-drug-candidates/2479035/Nanoform Finland and Nacuity Pharmaceuticals announced that they have signed a Technology Proof of Concept Agreement, with compensation on standard commercial terms. This will apply Nanoform’s nanoparticle CESS technology to enhance ophthalmic drug delivery of Nacuity’s NPI-001 and N
- UK Real-World Data Show COVID-19 Vaccine Linked to Lower Infection, Hospitalization Rateshttps://modernod.com/news/uk-real-world-data-show-covid-19-vaccine-linked-to-lower-infection-hospitalization-rates/2478899/Data from new analyses were released Monday shedding light on the short-term impacts of COVID-19 vaccinations in the UK. One analysis from Public Health England’s (PHE) SIREN study appears to corroborate early evidence that Pfizer and BioNTech’s vaccine BNT162b2 offers high levels of
- J&J Submits Single-Dose COVID-19 Vaccine for EMA Reviewhttps://modernod.com/news/jj-submits-single-dose-covid-19-vaccine-for-ema-review/2478881/The European Medicines Agency announced Tuesday that it has received a conditional marketing application for Johnson & Johnson’s COVID-19 vaccine candidate Ad26.COV2.S, and that it intends to review the submission under an accelerated timetable. The regulator indicated that the fi
- J&J Files Single-Dose COVID-19 Vaccine for US Emergency Usehttps://modernod.com/news/jj-files-single-dose-covid-19-vaccine-for-us-emergency-use/2478836/Johnson & Johnson submitted a request to the FDA seeking an emergency-use authorization (EUA) for its COVID-19 vaccine candidate Ad26.COV2.S. Paul Stoffels, the company’s chief scientific officer, called the filing “a pivotal step toward reducing the burden of disease for people g
- EyeCare Associates of East Texas Announces Partnership With Private Equity Firm EyeCare Partnershttps://modernod.com/news/eyecare-associates-of-east-texas-announces-partnership-with-private-equity-firm-eyecare-partners/2478721/Brown Gibbons Lang & Company (BGL) has announced a new partnership between EyeCare Associates of East Texas (ECA) and EyeCare Partners (ECP) resulting in the addition of ECA’s four Texas clinics to ECP’s national ne